SMC Accepts New Preventive Drug for Hereditary Angioedema

1 source1 article First seen 1 day ago Updated 1 day ago United Kingdom Truth score 38

Save Like Comments Compare coverage

Summary

Garadacimab, a once-monthly factor XIIa inhibitor, reduced monthly hereditary angioedema attack frequency by 87% in patients aged 12 years or older in a phase 3 trial. Medscape News UK

Description from Medscape.

Who is covering this

Medscape Center Factuality: Mostly factual US 1 day ago
SMC Accepts New Preventive Drug for Hereditary Angioedema
Garadacimab, a once-monthly factor XIIa inhibitor, reduced monthly hereditary angioedema attack frequency by 87% in patients aged 12 years or older in a phase 3 trial. Medscape News UK

Comments

Comments need JavaScript.

Truth score

38/100Weakly supported

Independent outlets: 1
Source reliability: 65/100
Sides of the spectrum covering it: 1/3
Propaganda risk: 0/100

How well the story is corroborated by independent, reliable outlets across the spectrum. Not a fact-check of each claim. How the truth score works

Coverage by lean

Centre 100%100%

Left: 0
Centre: 1
Right: 0
Not rated: 0

How lean is counted

Source quality

Average reliability: 65/100 (Mostly factual)
Low-credibility outlets: 0%
State media: 0%
Opinion pieces: 0%

Where ratings come from

Where the coverage comes from

United States1

In this story

Medscape News

Filter the stories

Sources Ratings and details

SMC Accepts New Preventive Drug for Hereditary Angioedema

Summary

Who is covering this

Comments

Summary

Who is covering this

Comments

Related stories

Needs-Led ADHD Triage Pilot Reports Early Results

SMC Accepts PD-1 Inhibitor for Locally Advanced Lung Cancer

Platelet Count, CRP Tied to Cancer Risk Across Ethnicities

Cardiometabolic MASLD Linked to Poorer Bariatric Op Outcomes

Spanish Study Finds Rise in Inflammatory Myopathy Admissions

Non-Cancer Diagnoses Before Cancer Linked to Varied Outcomes